SCHEMBL28636898

SCHEMBL28636898

CC(C)(C)OC(=O)N1CC[C@@H](Nc2cc(Cl)ncc2C(=O)O)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 7/20 0.49
BRD4 O60885 1/20 0.47
BTK Q06187 1/20 0.47
PIK3CD O00329 2/20 0.45
CNR1 P21554 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PIK3CA P42336 1/20 0.44
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29894214 1.00 USP30 (0.49) USP30BRD4BTKPIK3CDCNR1
SCHEMBL18341494 1.00 USP30 (0.49) USP30BRD4BTKPIK3CDCNR1
SCHEMBL23301762 1.00 USP30 (0.49) USP30BRD4BTKPIK3CDCNR1
SCHEMBL12280321 0.94 USP30 (0.47) USP30BRD4BTKPIK3CDCNR1
SCHEMBL24950095 0.94 USP30 (0.47) USP30BRD4BTKPIK3CDCNR1
SCHEMBL12280097 0.94 ALDH1A1 (0.50) USP30BRD4CNR1MEN1KMT2A
SCHEMBL30194552 0.93 USP30 (0.44) USP30BRD4BTKPIK3CDCNR1
SCHEMBL30194622 0.93 USP30 (0.44) USP30BRD4BTKPIK3CDCNR1
SCHEMBL12280016 0.92 IRAK4 (0.42) USP30BRD4BTKCNR1MEN1
SCHEMBL12279993 0.91 PARP1 (0.47) USP30BRD4BTKPIK3CDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051677-B1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECH LTD (GB) 2026-03-18 EP disclosed
US-12509457-B2 Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-12-30 US disclosed
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-01-19 US disclosed
CN-109641906-B Heteroaryl substituted aminopyridine compounds 百时美施贵宝公司 2021-10-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 SIK2, SIK1, SIK3 USP30 4590/4885BRD4 257/4885BTK 553/4885
US-12509457-B2 Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 SIK2, SIK1, SIK3 USP30 4703/4885BRD4 665/4885BTK 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.